Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cue Biopharma (CUE) Shares Outstanding (Weighted Average) (2017 - 2025)

Cue Biopharma's Shares Outstanding (Weighted Average) history spans 9 years, with the latest figure at $90.3 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 79.49% year-over-year to $90.3 million; the TTM value through Sep 2025 reached $90.3 million, up 79.49%, while the annual FY2024 figure was $56.3 million, 23.11% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q3 2025 was $90.3 million at Cue Biopharma, down from $95.5 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $95.5 million in Q2 2025 and bottomed at $30.4 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Weighted Average) is $44.7 million (2023), against an average of $47.9 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) increased 4.77% in 2021 before it skyrocketed 90.25% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $31.3 million in 2021, then grew by 13.95% to $35.6 million in 2022, then grew by 28.35% to $45.8 million in 2023, then grew by 23.11% to $56.3 million in 2024, then surged by 60.26% to $90.3 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's Shares Outstanding (Weighted Average) are $90.3 million (Q3 2025), $95.5 million (Q2 2025), and $74.3 million (Q1 2025).